Pharmaceutical

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical…

10 months ago

Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023

mTNX-1700 (mTFF2-MSA) suppresses tumor growth and increases survival rates in preclinical colorectal cancer models mTNX-1700 shows single agent activity and…

10 months ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company – – Data anticipated in the…

10 months ago

Cosmos Health Announces Strategic Collaboration with C.A.PAPAELLINAS Group

CHICAGO, IL / ACCESSWIRE / September 20, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

10 months ago

GE HealthCare Shares Key Focus Areas and Future Goals in its Inaugural Sustainability Report

First Sustainability Report since becoming an independent company in January 2023 underscores the Company’s commitment to corporate responsibility and embodies…

10 months ago

Scientific Industries Appoints Bioprocessing Industry Veteran as New Strategic Advisor

John Nicols brings 30+ years of experience growing biotechnology and specialty chemical companiesBOHEMIA, NY / ACCESSWIRE / September 20, 2023…

10 months ago

Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology

Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technologyORLANDO, FL / ACCESSWIRE / September 20, 2023 /…

10 months ago

Parexel’s Amy McKee, M.D. Named to 2023 PharmaVoice 100

Company’s Chief Medical Officer and FDA veteran receives distinguished award for notable contributions to clinical researchDURHAM, N.C., Sept. 20, 2023…

10 months ago

Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity

BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical…

10 months ago